Gemzar

(Gemcitabine)

ApprovedSmall molecule

Gemcitabine is a chemotherapy drug used to treat certain types of cancer, including pancreatic cancer, breast cancer, and lung cancer, by slowing or stopping the growth of cancer cells.[2] Gemzar is currently approved and in use across 162 indications[4].[1]

Gemzar is one of 1593 small molecule programs targeting Glioma. It is currently in Approved.

162

Indications

1,518

Total Trials

Active Trials

1,592

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Collecting Duct CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Peritoneum CancerApproved

Urinary Bladder CarcinomaApproved

Colorectal CarcinomaActive, not recruiting

Malignant Tumor of NasopharynxApproved

Non-Hodgkins LymphomaApproved

Uterine LeiomyosarcomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

Collecting Duct CarcinomaPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 2

Active, not recruiting

Peritoneum CancerApproved

Approved

Urinary Bladder CarcinomaApproved

Approved

Colorectal CarcinomaPhase 2

Active, not recruiting

Malignant Tumor of NasopharynxApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

Showing 10 of 162 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Approved

92 2

Halaven

Eisai

Preclinical

38 3

Trodelvy

Gilead

Preclinical

37 4

Tecentriq

Roche

Preclinical

36 5

Tykerb

GSK

Preclinical

80 6

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 7

Adriamycin

GGynecologic Oncology Group

Preclinical

87 8

Avastin

Prolia

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Breast Cancer

NCT03734029

Phase 3Recruiting

Nab-Paclitaxel

NCT03257033

Q4 2026

Phase 1/2Active, not recruiting

Bladder Cancer

NCT04179162

Phase 1Recruiting

Pancreatic Cancer

NCT06454383

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Phase 1/2Active, not recruiting

Bladder Cancer

NCT02989584

Clinical

Trials by Indication[1]

Pancreatic Cancer36 trials

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Completed·PPiramal Enterprises Limited·Phase 1/2·NCT00898287·23 enrolled

Show 33 more trials

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Completed·NNYU Langone Health·Phase 2·NCT00696696·45 enrolled

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Completed·BBaki Topal·Phase 2·NCT04156087·12 enrolled

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer

Unknown status·JJean-Luc Van Laethem·Phase 1·NCT01713218·21 enrolled

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Unknown status·BBetta Pharmaceuticals Co., Ltd.·Phase 1·NCT02024633·24 enrolled

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Completed·HHitendra Patel·Phase 2·NCT03697564·2 enrolled

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Completed·HHerlev Hospital·Phase 1/2·NCT04247165·55 enrolled

Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT00593866·50 enrolled

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04216758·300 enrolled

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT06199466·4 enrolled

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07283705·60 enrolled

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

Completed·SSwedish Medical Center·Phase 1·NCT00316420·20 enrolled

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Completed·AAgensys, Inc.·Phase 2·NCT01608711·2 enrolled

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00057876·74 enrolled

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Unknown status·—·Phase 2·NCT04902261·140 enrolled

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07079228·602 enrolled

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT02154737·24 enrolled

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Unknown status·FFudan University·Phase 3·NCT02506842·300 enrolled

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

Unknown status·SSamsung Pharmaceutical Co., Ltd.·Phase 3·NCT02854072·148 enrolled

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Completed·OOsaka Medical Center for Cancer and Cardiovascular Diseases·Phase 1·NCT02272738·54 enrolled

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

Unknown status·UUS Oncology Research·Phase 1·NCT01934634·24 enrolled

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Recruiting·—·Phase 1·NCT06454383·19 enrolled

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche··NCT01782690·338 enrolled

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Recruiting·FFudan University·Phase 2·NCT06196788·30 enrolled

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Terminated·—·Phase 1·NCT03520790·36 enrolled

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02017015·83 enrolled

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

Terminated·NNewLink Genetics Corporation·Phase 2·NCT02405585·10 enrolled

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00673504·105 enrolled

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Completed·—·Phase 1/2·NCT01506973·119 enrolled

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1/2·NCT06662669·120 enrolled

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06080854·108 enrolled

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Terminated·—·Phase 2·NCT03848182·10 enrolled

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Terminated·—·Phase 1·NCT03519308·3 enrolled

Breast Cancer16 trials

Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00480597·141 enrolled

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT04191135·462 enrolled

Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00244933·19 enrolled

Show 13 more trials

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191373·66 enrolled

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer

Completed·—·Phase 2·NCT02263495·118 enrolled

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Terminated·HHellenic Oncology Research Group·Phase 3·NCT00440622·90 enrolled

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Completed·KKari Kendra·Phase 2·NCT00201760·10 enrolled

Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00316199·60 enrolled

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT03734029·557 enrolled

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Completed·NNektar Therapeutics·Phase 3·NCT02915744·178 enrolled

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

Completed·WWest German Study Group·Phase 2·NCT01815242·336 enrolled

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00128310·252 enrolled

Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191789·65 enrolled

Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00431106·144 enrolled

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02755272·87 enrolled

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00063570·73 enrolled

Lymphoma12 trials

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting·SSecuraBio·Phase 3·NCT06522737·124 enrolled

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT02701673

GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma

Unknown status·SSun Yat-sen University·Phase 2·NCT01991158·30 enrolled

Show 9 more trials

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Completed·WWashington University School of Medicine·Phase 1·NCT02181218·24 enrolled

Study of Lacutamab in Peripheral T-cell Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04984837·56 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT02295722·100 enrolled

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03259503·50 enrolled

Gemcitabine for Marginal Zone Lymphoma

Terminated·—·Phase 2·NCT00337259·43 enrolled

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04917250·15 enrolled

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT02436707·129 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Biliary Tract Cancer9 trials

GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer

Unknown status·—·Phase 2·NCT01859728·48 enrolled

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06001658·27 enrolled

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT06708858·35 enrolled

Show 6 more trials

Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

Completed· Sanofi logo

Sanofi·Phase 2·NCT00753675·174 enrolled

Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

Completed·KKansai Hepatobiliary Oncology Group·Phase 1·NCT01291615·6 enrolled

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT02711553·309 enrolled

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT03046862·31 enrolled

Pembrolizumab in Biliary Tract Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03260712·50 enrolled

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Non-Small Cell Lung Cancer9 trials

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT01077713·86 enrolled

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Terminated·WWestern Regional Medical Center·Phase 2·NCT01860040·1 enrolled

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00735904·38 enrolled

Show 6 more trials

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT00940875·54 enrolled

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01160744·280 enrolled

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00560573·46 enrolled

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Terminated· Roche logo

Roche·Phase 3·NCT02409355·8 enrolled

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

65 more indications

Bladder Cancer9 trials

Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490880·2 enrolled

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT04179162·54 enrolled

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Completed·AAchieve Life Sciences·Phase 2·NCT01454089·183 enrolled

Show 6 more trials

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01916109·4 enrolled

Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer

Unknown status·RRuijin Hospital·Phase 2·NCT04909775·40 enrolled

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06960577·150 enrolled

Chemoablation for Low-Grade Bladder Cancer

Recruiting·EEkaterina Laukhtina·Phase 2·NCT07019220·47 enrolled

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02989584·54 enrolled

Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers

Active, not recruiting·TTata Memorial Hospital·Phase 2/3·NCT02867865·124 enrolled

Gemcitabine8 trials

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00540579·23 enrolled

Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine

Completed·NNathan Bahary, MD·Phase 2·NCT01978184·104 enrolled

Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191100·515 enrolled

Show 5 more trials

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Recruiting·SShanghai Zhongshan Hospital··NCT07291063·50 enrolled

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

Completed·FFudan University·Phase 2·NCT01810367·84 enrolled

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03717155·43 enrolled

Adavosertib and Gemcitabine in Advanced Pancreatic

Withdrawn·—·Phase 2·NCT05212025

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2/3·NCT04066491·309 enrolled

Pancreatic Adenocarcinoma8 trials

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma

Completed·NNational Taiwan University Hospital·Phase 1/2·NCT00154791·45 enrolled

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01431794·23 enrolled

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Unknown status·NNovoCure GmbH·Phase 1/2·NCT01971281·40 enrolled

Show 5 more trials

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02109445·3 enrolled

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Completed·SSynCore Biotechnology Co., Ltd.·Phase 3·NCT03126435·218 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Unknown status·—·Phase 1·NCT03703089·21 enrolled

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Recruiting·AAshish Manne·Phase 2·NCT05624918·38 enrolled

Chemotherapy6 trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT07024615·25 enrolled

Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 3·NCT00499109·275 enrolled

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

Show 3 more trials

A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Unknown status·Ee-Therapeutics PLC·Phase 1·NCT02423239·112 enrolled

Chemotherapy and G-CSF for Mobilization

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03442673·137 enrolled

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05451043·62 enrolled

Ovarian Cancer5 trials

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer

Unknown status·CCureLab Oncology·Phase 2·NCT05979298·40 enrolled

Show 2 more trials

A Study LY2228820 for Recurrent Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01663857·118 enrolled

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Terminated· Eisai logo

Eisai·Phase 1/2·NCT01133756·7 enrolled

Advanced Solid Tumors5 trials

A Safety Study in Participants With Advanced Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01284335·234 enrolled

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00648648·206 enrolled

Show 2 more trials

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT03102320·173 enrolled

Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors

Completed·UUniversity of Cincinnati·Phase 1·NCT02071537·24 enrolled

Nasopharyngeal Carcinoma4 trials

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05587374·490 enrolled

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT04447612·118 enrolled

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·FFudan University·Phase 2·NCT04517214·100 enrolled

Show 1 more trial

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT05524168·41 enrolled

Diffuse Large B-Cell Lymphoma3 trials

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02692248·64 enrolled

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02060656·92 enrolled

Pancreatic Ductal Adenocarcinoma3 trials

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 1/2·NCT06904378·61 enrolled

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 3·NCT02715804·492 enrolled

Metastatic Urothelial Cancer3 trials

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT04223856·886 enrolled

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Completed·IInstitut Claudius Regaud·Phase 2/3·NCT02240017·46 enrolled

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06592326·460 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Withdrawn·DDaiichi Pharmaceuticals·Phase 1·NCT00072228

A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02825940·120 enrolled

Urothelial Cancer2 trials

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Completed·UUniversity Health Network, Toronto·Phase 2·NCT03520231·6 enrolled

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05911295·412 enrolled

Small Cell Lung Cancer2 trials

Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00192036·49 enrolled

Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine

Completed· Sanofi logo

Sanofi·Phase 2·NCT00753714·124 enrolled

Adenocarcinoma2 trials

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00844649·861 enrolled

Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191503·30 enrolled

Metastatic Solid Tumors2 trials

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Terminated· Roche logo

Roche·Phase 2·NCT03386721·256 enrolled

Pancreas Cancer2 trials

Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

Completed·TTony Bekaii-Saab·Phase 2·NCT00417976·42 enrolled

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

Completed·HHacettepe University·Phase 2·NCT03807999·125 enrolled

Nab-paclitaxel2 trials

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting·RRenovoRx·Phase 3·NCT03257033·190 enrolled

Scheduling Nab-paclitaxel With Gemcitabine

Completed·CCCTU- Cancer Theme·Phase 2·NCT03529175·146 enrolled

Lung Cancer2 trials

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Unknown status·—·Phase 2·NCT00150657·45 enrolled

Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490659·13 enrolled

Lenalidomide2 trials

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00837031·72 enrolled

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179751·50 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05672537·70 enrolled

Newly Diagnosed1 trial

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated·IIGM Biosciences, Inc.·Phase 1·NCT04553692·272 enrolled

Advanced Soft-tissue Sarcoma1 trial

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Recruiting·AAsociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas·Phase 2·NCT06114004·88 enrolled

Cervical Carcinoma1 trial

Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

Completed·UUniversity of California, San Diego·Phase 1·NCT01554410·35 enrolled

Sarcoma1 trial

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Completed·MMorphotek·Phase 2·NCT01574716·209 enrolled

Gastrointestinal1 trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1/2·NCT06445062·1,130 enrolled

Toxicity1 trial

A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival

Completed· Roche logo

Roche·Phase 2·NCT00461708·153 enrolled

Urothelial Carcinoma1 trial

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Completed·HHoosier Cancer Research Network·Phase 2·NCT01524991·36 enrolled

Relapsed or Refractory1 trial

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT03593018·86 enrolled

Radiotherapy1 trial

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06472037·30 enrolled

Pancreatic1 trial

Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours

Unknown status·PPD Dr. med. Volker Heinemann·Phase 2·NCT01728818·119 enrolled

Locally-advanced Rectal Cancer1 trial

Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer

Unknown status·KKing Faisal Specialist Hospital & Research Center·Phase 2·NCT02919878·25 enrolled

Patients With Advanced Solid Tumors1 trial

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Completed·MMerrimack Pharmaceuticals·Phase 1·NCT01447225·43 enrolled

Medulloblastoma1 trial

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01878617·660 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Brentuximab Vedotin1 trial

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT03496779·71 enrolled

Fallopian Tube Cancer1 trial

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191646·919 enrolled

Refractory Sarcoma1 trial

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02945800·59 enrolled

Muscle-invasive Urothelial Cancer of the Bladder1 trial

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Active, not recruiting·NNYU Langone Health·Phase 2·NCT02621151·60 enrolled

Advanced Cancer1 trial

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Colorectal Carcinoma1 trial

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Unknown status·—·Phase 2·NCT04668976·100 enrolled

Advanced/Metastatic Cancer1 trial

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02857270·210 enrolled

Radiation Therapy1 trial

Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC

Terminated·—·Phase 2·NCT02254681·6 enrolled

Efficacy1 trial

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Active, not recruiting·PPeptomyc S.L.·Phase 1·NCT06059001·26 enrolled

Soft Tissue Sarcoma1 trial

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06370871

Advanced Biliary Tract Carcinoma1 trial

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05822453·20 enrolled

Osteosarcoma1 trial

Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Recruiting·EEmory University·Phase 1·NCT07144254·24 enrolled

First Line Therapy1 trial

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruiting·SSun Yat-sen University·Phase 2/3·NCT04890522·622 enrolled

Metastatic Colorectal Cancer1 trial

Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00220155·16 enrolled

Effectiveness1 trial

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Recruiting·NNational Cancer Center, Korea·Phase 2·NCT06388720·82 enrolled

Efficacy and Safety1 trial

Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT03025880·36 enrolled

Hematopoietic Cell Transplant1 trial

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled

Malignancies1 trial

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Recruiting·AALX Oncology Inc.·Phase 1/2·NCT07007559·80 enrolled

Carcinoma of Unknown Primary1 trial

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135

Randomized Controlled Trial1 trial

Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy

Completed·HHuazhong University of Science and Technology·Phase 3·NCT00644618·120 enrolled

Malignant Pleural Mesothelioma1 trial

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Completed·EETOP IBCSG Partners Foundation·Phase 3·NCT02991482·144 enrolled

HER2-positive Advanced Solid Tumors1 trial

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Unknown status·SSUNHO（China）BioPharmaceutical CO., Ltd.·Phase 1/2·NCT04934514·97 enrolled

Cancer1 trial

Safety Study of SEA-CD40 in Cancer Patients

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02376699·159 enrolled

Solid Tumors1 trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting·VVerastem, Inc.·Phase 1/2·NCT07020221·295 enrolled

Advanced Cancers1 trial

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Completed·TTrishula Therapeutics, Inc.·Phase 1·NCT03884556·56 enrolled

Cancer of the Pancreas1 trial

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00020345

Gallbladder Carcinoma1 trial

Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma

Unknown status·FFudan University·Phase 3·NCT02798510·140 enrolled

Ovarian Carcinoma1 trial

Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Completed·HHellenic Oncology Research Group·Phase 1/2·NCT00429559·31 enrolled

Leiomyosarcoma1 trial

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02303262·20 enrolled

Liver Cancer1 trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

Unspecified1 trial

M6620 First in Human Study

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 1·NCT02157792·200 enrolled

Regulatory

FDA Approval Timeline[5]

May 15, 1996

GEMZAR

NDA NDA020509

Aug 4, 2011

GEMCITABINE HYDROCHLORIDE

NDA NDA200795

Aug 3, 2017

GEMCITABINE HYDROCHLORIDE

NDA NDA209604

Jul 16, 2018

INFUGEM

NDA NDA208313

Jun 27, 2025

AVGEMSI

NDA NDA219920

Sep 9, 2025

INLEXZO

NDA NDA219683

Sources

References

[1]
ClinicalTrials.gov — 1518 trial records for Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gemzar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219683). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Gemzar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Patent Landscape[6]

Patent Cliff

Jun 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12403086Jun 28, 2030

12576253Dec 17, 2030

8679094Apr 15, 2032

9241948Jul 1, 2033

10729823Aug 19, 2034

1 more patents

12447241Aug 19, 2034